# Public discontentment towards rising medicine prices will drive price cuts in Indonesia

- Link: https://www.thailand-business-news.com/health/156554-public-discontentment-towards-rising-medicine-prices-will-drive-price-cuts-in-indonesia
- Published: 2024-08-16T07:23:00+07:00
- Author: News Desk

Anticipated reforms in pharmaceutical policy in Indonesia aim to address the issue
of high medicine prices in the country. The reforms are expected to focus on measures
to improve access to affordable medicines and ensure the sustainability of the national
health insurance system.

## **Key View**

 * Public discontentment towards rising medicine prices will drive price cuts in
   Indonesia.
 * We expect greater pharmaceutical policy reforms in Indonesia to address inefficiencies
   in public procurement and distribution of medicines.
 * Despite potential deterrent effects of lowering medicine prices, greater pricing
   transparency will increase Indonesia’s market attractiveness supporting pharmaceutical
   sector growth. 

**Public discontentment towards rising medicine prices will drive price cuts in 
Indonesia. **In early July 2024,** **Indonesia’s outgoing president, Joko Widodo
directed his cabinet to address the issue of high drug prices and medical equipment
costs in Indonesia. The directive came in response to growing public concerns over
the affordability of essential medicines and healthcare services in the country.

ADVERTISEMENT

Medicine prices in Indonesia have been significantly higher compared to neighboring
countries, particularly Malaysia. For instance, common medications prescribed for
chronic conditions such as hypertension and high blood pressure are priced two to
nearly four times higher in Indonesia than in Malaysia. Malaysia’s stringent price
controls, external reference pricing and effective capping of trade margins for 
drugs in the country has resulted in reduced price of medicines.

The disparity in medicines prices between Indonesia and Malaysia has raised several
questions regarding the underlying factors contributing to these differences and
the broader implications for healthcare access. As such, we expect cuts to medicine
prices due to increased public focus on the topic which will bring the market in
line with regional standards.

### Related**Posts**

###  󠀁[Offering incentives for companies on the Green List with the IDX Green Equity designation](https://www.thailand-business-news.com/asean/indonesia/331229-offering-incentives-for-companies-on-the-green-list-with-the-idx-green-equity-designation)󠁿

###  󠀁[Indonesia Representative Offices: What They Can and Cannot Do](https://www.thailand-business-news.com/asean/324537-indonesia-representative-offices-what-they-can-and-cannot-do)󠁿

###  󠀁[TAT highlights “Healing is the New Luxury” at the Tourism Expo Japan 2026](https://www.thailand-business-news.com/health/331124-tat-highlights-healing-is-the-new-luxury-at-the-tourism-expo-japan-2026)󠁿

###  󠀁[Which Sector-Specific Licenses Do Foreign Investors Need in Indonesia?](https://www.thailand-business-news.com/asean/328338-which-sector-specific-licenses-do-foreign-investors-need-in-indonesia)󠁿

In Indonesia, the rising cost of medications has become a pressing issue, prompting
the government to consider significant pharmaceutical policy reforms. The high prices
of essential medicines not only burden patients but also hinder access to healthcare
services. As a response, the Indonesian Ministry of Health is exploring new strategies
aimed at regulating prices, enhancing transparency, and ensuring that essential 
drugs are affordable for all citizens.

Proposed reforms include the implementation of price controls on critical medications,
which would cap the maximum allowable prices charged by manufacturers and distributors.
Additionally, the government plans to strengthen procurement processes, promoting
bulk purchasing agreements to leverage better pricing. By involving a wider array
of stakeholders, including healthcare professionals and patient advocacy groups,
these reforms aim to create a more equitable pharmaceutical landscape.

If successfully implemented, these expected policy changes could dramatically improve
patient access to vital medications in Indonesia. This initiative not only reflects
a commitment to public health but also recognizes the necessity of balancing pharmaceutical
company sustainability with the needs of patients, ultimately fostering a healthier
population.
[Read More](https://www.fitchsolutions.com/bmi/pharmaceuticals/expected-pharmaceutical-policy-reforms-will-address-high-medicine-prices-indonesia-09-08-2024)